Abstract
In this present work, 5-chloro-3-(substituted-benzylidene)indolin-2-one and 1-benzyl-5-chloro-3-(substitutedbenzylidene) indolin-2-one derivatives were synthesized and evaluated for their inhibitory activity against Src Family Kinases (SFKs) such as Fyn, Lyn and Hck. 5-Chloro-3-(substituted)indolin-2-ones (3a - 6a) and 1-benzyl-5-chloro-3- (substituted-benzylidene)indolin-2-ones (3b - 6b) were prepared by condensation of 5-chloro oxindole and 1-benzyl-5- chloro oxindole with the equivalent amount of aldehydes in EtOH in the presence of piperidine. Among all compounds, only 4a, 5b and 6b were found slightly active against Fyn with 13 - 16% inhibitions at 0.1 and 0.01 mM concentrations. Compounds did not exhibit any inhibitory potency against Lyn and Hck. Docking study of compounds was performed to evaluate receptor-binding properties of compounds and the results showed that the most active compound 6b binds into the active site of Fyn, which has similar binding mode with potent inhibitor PP2.
Keywords: Oxindole derivatives, Inhibition of SFKs, Synthesis, Selectivity, Docking, Activity.
Letters in Drug Design & Discovery
Title:Synthesis, Biological and Computational Evaluation of Novel Oxindole Derivatives as Inhibitors of Src Family Kinases
Volume: 10 Issue: 8
Author(s): Zühal Kilic-Kurt, Arzu Onay-Besikci and Sureyya Olgen
Affiliation:
Keywords: Oxindole derivatives, Inhibition of SFKs, Synthesis, Selectivity, Docking, Activity.
Abstract: In this present work, 5-chloro-3-(substituted-benzylidene)indolin-2-one and 1-benzyl-5-chloro-3-(substitutedbenzylidene) indolin-2-one derivatives were synthesized and evaluated for their inhibitory activity against Src Family Kinases (SFKs) such as Fyn, Lyn and Hck. 5-Chloro-3-(substituted)indolin-2-ones (3a - 6a) and 1-benzyl-5-chloro-3- (substituted-benzylidene)indolin-2-ones (3b - 6b) were prepared by condensation of 5-chloro oxindole and 1-benzyl-5- chloro oxindole with the equivalent amount of aldehydes in EtOH in the presence of piperidine. Among all compounds, only 4a, 5b and 6b were found slightly active against Fyn with 13 - 16% inhibitions at 0.1 and 0.01 mM concentrations. Compounds did not exhibit any inhibitory potency against Lyn and Hck. Docking study of compounds was performed to evaluate receptor-binding properties of compounds and the results showed that the most active compound 6b binds into the active site of Fyn, which has similar binding mode with potent inhibitor PP2.
Export Options
About this article
Cite this article as:
Kilic-Kurt Zühal, Onay-Besikci Arzu and Olgen Sureyya, Synthesis, Biological and Computational Evaluation of Novel Oxindole Derivatives as Inhibitors of Src Family Kinases, Letters in Drug Design & Discovery 2013; 10 (8) . https://dx.doi.org/10.2174/15701808113109070023
DOI https://dx.doi.org/10.2174/15701808113109070023 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Proteasome Inhibitors in Cancer Therapy
Current Drug Targets Epidemiology of Upper Gastrointestinal Damage Associated with Low-Dose Aspirin
Current Pharmaceutical Design BTX AgilePulse<sup>TM</sup> System is an Effective Electroporation Device for Intramuscular and Intradermal Delivery of DNA Vaccine
Current Gene Therapy Pleural Involvement Due to Metastatic Melanoma: A Rare Complication and Literature Review
Current Respiratory Medicine Reviews Rational Targeting of the Urokinase Receptor (uPAR): Development of Antagonists and Non-Invasive Imaging Probes
Current Drug Targets Effect of Salinomycin on Expression Pattern of Genes Associated with Apoptosis in Endometrial Cancer Cell Line
Current Pharmaceutical Biotechnology Onco-Surgical Management of Colo-Rectal Liver Metastases in Older Patients: A New Frontier in the 3<sup>rd</sup> Millennium
Anti-Cancer Agents in Medicinal Chemistry Anti-Cancer Compounds from Terrestrial and Marine Resources -In silico and Experimental Studies
Current Computer-Aided Drug Design The Emerging Role of NRAS Mutations in Colorectal Cancer Patients Selected for Anti-EGFR Therapies
Reviews on Recent Clinical Trials Drosophila Neoplasias: Clues Towards the Understanding of Human Cancers
Current Genomics Antibody-Drug Conjugate Targets
Current Cancer Drug Targets Cu-mediated synthesis of 2,3-dihydro-1H-pyrrolo[3,2,1-ij]quinolin-1-ones as potential inhibitors of sirtuins
Letters in Drug Design & Discovery Dendritic Cells in Esophageal Adenocarcinoma: The Currently Available Information and Possibilities to use Dendritic Cells for Immunotherapeutic Approaches
Current Pharmaceutical Design Tumor Intracellular Redox Status and Drug Resistance-Serendipity or a Causal Relationship?
Current Pharmaceutical Design Hypoxic Culture Conditions for Mesenchymal Stromal/Stem Cells from Wharton’s Jelly: A Critical Parameter to Consider in a Therapeutic Context
Current Stem Cell Research & Therapy Molecular Evidence of Compound Kushen Injection Against Lung Cancer: A Network Pharmacology-Based Investigation from Western Medicine to Traditional Medicine
Anti-Cancer Agents in Medicinal Chemistry NF-κB-IKKβ Pathway as a Target for Drug Development: Realities, Challenges and Perspectives
Current Drug Targets Novel Genetic and Peptide-Based Strategies Targeting the Bcl-2 Family, an Update
Recent Patents on DNA & Gene Sequences Spotlight on Circadian Genes and Colorectal Cancer Crosstalk
Endocrine, Metabolic & Immune Disorders - Drug Targets Therapeutic Potential of Polyphenols and their Nanoformulations in the Treatment of Colorectal Cancer
Anti-Cancer Agents in Medicinal Chemistry